D.E. Shaw & Co
BXRX

D.E. Shaw & Co’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

D.E. Shaw & Co’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,880
Closed -$416K – 6055
2022
Q1 		$416K Buy
+5,880
New +$1.09M ﹤0.01% 4477
2021
Q4 		– Sell
-23
Closed -$18K – 5873
2021
Q3 		$18K Sell
23
-7
-23% -$6.09K ﹤0.01% 4905
2021
Q2 		$32K Buy
+30
New +$39.3K ﹤0.01% 4662
2021
Q1 		– Sell
-95
Closed -$134K – 4637
2020
Q4 		$134K Buy
+95
New +$194K ﹤0.01% 3782
2020
Q2 		– Sell
-34
Closed -$118K – 4336
2020
Q1 		$118K Sell
34
-23
-40% -$217K ﹤0.01% 3762
2019
Q4 		$556K Buy
+57
New +$486K ﹤0.01% 3340

Other funds holding BXRX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

D.E. Shaw & Co's BXRX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2022, closing a stake of 5,880 shares — an estimated $416K sold.

D.E. Shaw & Co first reported a position in BXRX in Q4 2019 and held it in 6 quarters. The position peaked at $556K in Q4 2019. 19 funds tracked by Wall St. Rank hold BXRX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 5,880 Baudax Bio, Inc. Common Stock shares in Q2 2022, an estimated $416K.
  • D.E. Shaw & Co first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 6 quarters.
  • D.E. Shaw & Co's Baudax Bio, Inc. Common Stock position peaked at $556K in Q4 2019.
  • 19 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.